UTI's Convertible Bonds Are a Dilution Machine, Not Patient Capital

UTI Inc., a South Korean smartphone glass maker, priced its latest series of convertible bonds at 4,795 won per share. The series before that — issued just two months earlier — was priced at 21,178 won. The one before that, at 24,575 won.

A conversion price is the price at which bondholders can swap their bonds for company stock. Each series was issued at a price tied to whatever the stock was trading near at the time. The stock was falling, so the prices fell. The conversion price on the newest bonds is less than one-quarter of what it was on the series issued two months prior.

That doesn't just look bad. It's a signal that the company's capital structure has become a machine that turns cash shortages into equity dilution — and that machine has a built-in accelerator.

What the machine is

UTI manufactures cover glass for smartphone cameras, fingerprint sensors, and other mobile components. It's listed on KOSDAQ, South Korea's growth-market exchange. The company has been losing money for five consecutive years, with operating losses of 48.3 billion won last year on 20 billion won in sales.

When a company can't generate enough cash and doesn't want to sell stock at a price that angers existing shareholders, one option is to issue convertible bonds — debt that pays little or no interest but lets bondholders convert into stock later. The company gets cash now, and the conversion happens at a price above today's market, which means the bonds only convert into shares if the stock eventually recovers. It looks like a compromise: the company avoids immediate dilution, and the bondholders get a call option on the stock.

The problem UTI's bonds have is a repricing clause.

Every 7 months from issuance, if the stock price has fallen, the conversion price adjusts downward — to no lower than 70% of the original price. This was supposed to be a courtesy, giving bondholders a path to conversion even if the stock drifts lower. But in a sustained decline, the repricing clause does something else. A lower conversion price means each bond converts into more shares. More shares on the other side means more dilution. More dilution means more selling pressure if those bonds eventually convert. The cycle has a name: repricing, and it's built into the contract.

On UTI's earlier series, the repricing already happened. The first series of bonds, originally priced at 36,559 won per share, was repriced down to 25,592 won. The second series went from 30,654 to 21,458 won. These repricings expanded the number of shares issuable upon conversion by hundreds of thousands each.

The scale

Here's what accumulates when you keep issuing new bonds to cover old ones, at lower and lower conversion prices. UTI has issued convertible bonds six times in roughly two years. As of mid-August, the outstanding balance across all unpaid series reached 97 billion won.

That is 4.85 times the company's annual revenue of 20 billion won. It is 1.5 times the company's total equity of about 65 billion won. The company has also negotiated to repay its largest early-redemption obligation — 54.1 billion won in bonds — in three staggered installments, with a 15% annual interest rate on the deferred amounts. It couldn't pay in full, so it split the bill and added a cost that would make a payday lender look reasonable.

The free cash flow burned 110 billion won last year. The 3 billion won raised in a small equity offering in August 2026 — which saw the stock spike 30% on limit-up one day and fall 26% the next — covers roughly one month of that burn.

Why this matters

The basic point is that UTI's convertible bonds are not a bridge to profitability. They're a way to keep the company solvent while the conversion price drifts closer and closer to the stock price, which means the bonds convert into more and more shares. The repricing clause ensures that even a flat or slowly falling stock doesn't save existing shareholders from dilution — because the conversion price will chase the market price downward, mechanically, every 7 months.

When all outstanding bonds eventually convert, they represent roughly 22.5% of the total issued shares. That's not a hypothetical overhang. The company is structurally obligated to create those shares, or to find cash to pay bondholders in full — and finding 97 billion won in cash is, as of now, the harder path.

The newest series of bonds also carries drag-along rights, which let bondholders sell shares alongside the controlling shareholder if a sale happens. That's a control hedge for bondholders who know their investment is tied to a company whose equity value keeps shrinking. The newest series can also be put back to the company for early repayment starting July 2028. That means in roughly two years, bondholders can say: we're done waiting, pay us back. And then the company will face the same question again — issue more bonds, raise equity, or convert.

What you're looking at

UTI is a company that raised money to build a thin-glass production line aimed at foldable phones and advanced display components — a capital-intensive bet that hasn't generated the revenue to cover the spending. The convertible bond structure was supposed to be patient capital. Instead, the repricing mechanics and the relentless cash burn have turned it into a series of shorter bridges at progressively lower prices, each one expanding the number of shares that will eventually be issued.

The share price has fallen roughly 91% over the past year, from a high of 29,300 won to the 2,400-won range. At those levels, the conversion prices on the outstanding bonds — many of them now in the 4,000-to-25,000 won range — sit above the current market price. That means conversion isn't profitable for bondholders today. But it also means the repricing clock keeps ticking. Every 7 months, the price adjusts downward, closer to where the stock actually trades, closer to the point where conversion becomes rational, closer to the dilution hitting existing shareholders.

For a retail investor, the structural takeaway isn't really about whether UTI's thin-glass technology is promising. The technology question matters, but it's downstream. The upstream fact is that the company's financing structure is a machine that converts operational losses into ever-larger equity commitments, with contractual repricing that ensures dilution even when the stock is falling. You can hope the product turnaround arrives before the cash runs out. But the capital structure doesn't reward patience the way it was supposed to — it penalizes it.